ARCUTIS BIOTHERAPEUTICS, INC. Operating Lease, Expense
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Operating Lease, Expense of $184.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-11-03
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-09-30 was $184.00K, a 1.08% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-06-30 was $177.00K, a 2.31% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-03-31 was $189.00K, a 10.53% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, expense for the quarter ending 2022-12-31 was $186.00K, a 9.41% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $716.00K, a 4.37% increase from fiscal 2021.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, expense for fiscal 2021 was $686.00K, a 13.95% increase from fiscal 2020.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, expense for fiscal 2020 was $602.00K, a 298.68% increase from fiscal 2019.
- ARCUTIS BIOTHERAPEUTICS, INC. operating lease, expense for fiscal 2019 was $151.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $184.00K 10-Q · filed 2023-11-03 | $361.00K derived: sum of 2 quarters · filed 2023-11-03 | $551.00K 10-Q · filed 2023-11-03 | $736.00K derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | $177.00K 10-Q · filed 2023-08-08 | $366.00K 10-Q · filed 2023-08-08 | $552.00K derived: sum of 3 quarters · filed 2023-08-08 | $738.00K derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-03-31 | $189.00K 10-Q · filed 2023-05-09 | $375.00K derived: sum of 2 quarters · filed 2023-05-09 | $561.00K derived: sum of 3 quarters · filed 2023-11-03 | $734.00K derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-12-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $372.00K derived: sum of 2 quarters · filed 2023-11-03 | $545.00K derived: sum of 3 quarters · filed 2023-11-03 | $716.00K 10-K · filed 2023-02-28 |
| 2022-09-30 | $186.00K 10-Q · filed 2023-11-03 | $359.00K derived: sum of 2 quarters · filed 2023-11-03 | $530.00K 10-Q · filed 2023-11-03 | $700.00K derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $173.00K 10-Q · filed 2023-08-08 | $344.00K 10-Q · filed 2023-08-08 | $514.00K derived: sum of 3 quarters · filed 2023-08-08 | $685.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $171.00K 10-Q · filed 2023-05-09 | $341.00K derived: sum of 2 quarters · filed 2023-05-09 | $512.00K derived: sum of 3 quarters · filed 2023-05-09 | $682.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $341.00K derived: sum of 2 quarters · filed 2023-02-28 | $511.00K derived: sum of 3 quarters · filed 2023-02-28 | $686.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $171.00K 10-Q · filed 2022-11-08 | $341.00K derived: sum of 2 quarters · filed 2022-11-08 | $516.00K 10-Q · filed 2022-11-08 | $723.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $170.00K 10-Q · filed 2022-08-04 | $345.00K 10-Q · filed 2022-08-04 | $552.00K derived: sum of 3 quarters · filed 2023-02-28 | $754.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $175.00K 10-Q · filed 2022-05-05 | $382.00K derived: sum of 2 quarters · filed 2023-02-28 | $584.00K derived: sum of 3 quarters · filed 2023-02-28 | $734.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $409.00K derived: sum of 2 quarters · filed 2023-02-28 | $559.00K derived: sum of 3 quarters · filed 2023-02-28 | $602.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $202.00K 10-Q · filed 2021-11-04 | $352.00K derived: sum of 2 quarters · filed 2021-11-04 | $395.00K 10-Q · filed 2021-11-04 | $437.00K derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $150.00K 10-Q · filed 2021-08-05 | $193.00K 10-Q · filed 2021-08-05 | $235.00K derived: sum of 3 quarters · filed 2022-02-22 | $277.00K derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $43.00K 10-Q · filed 2021-05-06 | $85.00K derived: sum of 2 quarters · filed 2022-02-22 | $127.00K derived: sum of 3 quarters · filed 2022-02-22 | $169.00K derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $84.00K derived: sum of 2 quarters · filed 2022-02-22 | $126.00K derived: sum of 3 quarters · filed 2022-02-22 | $151.00K 10-K · filed 2022-02-22 |
| 2019-09-30 | $42.00K 10-Q · filed 2020-11-05 | $84.00K derived: sum of 2 quarters · filed 2020-11-05 | $109.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $42.00K 10-Q · filed 2020-08-11 | $66.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $24.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |